Glutamate (Metabotropic) Group I Receptor Antagonists
| Cat. No. | Product Name / Activity |
|---|---|
| 5229 | ABP 688 |
| High affinity human mGlu5 antagonist | |
| 0904 | AIDA |
| Potent and selective group I mGlu antagonist | |
| 5614 | AZD 2066 |
| mGlu5 antagonist; orally bioavailable and brain penetrant | |
| 5613 | AZD 9272 |
| Potent and selective mGlu5 antagonist; brain penetrant | |
| 0323 | (S)-4-Carboxyphenylglycine |
| Competitive group I mGlu antagonist; also weak group II agonist | |
| 1028 | CPCCOEt |
| Selective non-competitive mGlu1 antagonist | |
| 2333 | JNJ 16259685 |
| Highly potent, mGlu1-selective non-competitive antagonist | |
| 1237 | LY 367385 |
| Selective mGlu1a antagonist | |
| 2390 | LY 456236 hydrochloride |
| Selective mGlu1 antagonist | |
| 1212 | MPEP hydrochloride |
| Potent mGlu5 antagonist; also positive allosteric modulator of mGlu4 receptors | |
| 2921 | MTEP hydrochloride |
| Potent and selective mGlu5 antagonist | |
| 4134 | NPS 2390 |
| Group I mGlu antagonist | |
| 1027 | PHCCC |
| Potent group I mGlu antagonist |
Our Metabotropic Glutamate Receptor review gives an overview of the pharmacological ligands used to study the mGlu receptors.
Request copyRequest PDF
Written by Prof David Nutt, this poster summarizes the brain circuits and neurotransmitter systems that are affected by the main classes of addictive drugs.
Request copyDownload PDFWritten by P. Skolnich et al
Our Depression poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder.
Request copyDownload PDF
Our Huntington's Disease (HD) poster summarizes the pathophysiology and molecular changes that occur in HD.
Request copyDownload PDFWritten by Clea Warburton and Zafar Bashir
Our Learning and Memory poster gives an overview of the cellular mechanisms underlying recognition memory and its links to long-term depression.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDF